NOVABAY PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.15 USD | -8.43% |
|
-31.71% | -55.88% |
Presentation Operator MessageOperator (Operator)Welcome to the NovaBay Pharmaceuticals Fourth ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
NovaBay Pharmaceuticals, Inc. develops and sells scientifically created and clinically proven eyecare and wound care products. Its product, Avenova Antimicrobial Lid and Lash Solution, has antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. It offers a portfolio of products for each step of the standard at home treatment regimen, including the Avenova Eye Health Support antioxidant-rich oral supplement, Avenova Lubricating Eye Drops for instant relief, NovaWipes by Avenova, Avenova Warm Eye Compress to soothe the eyes, and the i-Chek by Avenova to monitor physical eyelid health. It also manufactures and sells its proprietary form of hypochlorous acid for the wound care market with its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers and other injuries.
Calendar
07/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.15
USD
Average target price
91
USD
Spread / Average Target
+2,788.89%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -55.88% | 3.63M | |
| +48.64% | 56.65B | |
| -6.44% | 39.44B | |
| +37.77% | 39.03B | |
| +14.28% | 26.75B | |
| -11.17% | 26.86B | |
| -21.40% | 19.03B | |
| +25.64% | 12.26B | |
| +0.96% | 12.28B | |
| +27.04% | 12.04B |
- Stock Market
- Equities
- NBY Stock
- News NovaBay Pharmaceuticals, Inc.
- Transcript : NovaBay Pharmaceuticals, Inc., Q4 2020 Earnings Call, Mar 25, 2021
